摘要
目的研究帕利哌酮缓释片对首发精神分裂症患者血脂代谢的影响。方法对43例首发精神分裂症患者在使用帕利哌酮治疗前以及治疗4、8、12周后应用PANSS量表测定,并测量患者身高、体重、腰围、血脂、空腹血糖、OGTT后2小时血糖、血压。结果①治疗4周后,PANSS总分及各项因子分较治疗前均降低,差异有统计学意义(P<0.01)。②治疗8周和12周后患者的体重指数和腰围与治疗前比较有明显变化,差异有统计学意义(P<0.05);而血脂、空腹血糖、OGTT后2小时血糖、血压等指标在治疗前后无明显变化,差异无统计学意义(P>0.05)。结论①帕利哌酮缓释片不仅能明显改善首发精神分裂症患者的阳性症状,而且也改善患者阴性症状。②帕利哌酮缓释片对首发精神分裂症患者体重有一定影响,而对其它代谢指标无明显影响。
Objective To study the influence of paliperidone extended-release tablets on blood lipid metabolism of first-episode schizophrenia patients. Methods 43 patients with schizophrenia were treated with paliperidone extended-re- lease tablets. PANSS scale measurement, height, weight, waist circumference, blood lipid, fasting blood sugar, 2 h af- ter OGTT blood glucose and blood pressure were observed before and 4 weeks,8 weeks, 12 weeks after treatment. Re- suits PANSS score and various factors points 4 weeks after treatment were lower than that before （P^0.01）. The body mass index and waist circumference eight weeks and 12 weeks after treatment were more obvious changes （P〈0.05）. The blood lipid, fasting blood glucose, blood sugar 2 h after OGTT, blood pressure had no change before and after treat- ment （P^0. 05）. Conclusion Paliperidone extended-release tablets can significantly improve starting schizophrenia posi- tive symptoms and the negative symptoms. Paliperidone extended-release tablets for first-episode schizophrenia patients have certain influence to weight, and other metabolic indices have no obvious influence.
出处
《西部医学》
2013年第9期1386-1387,1390,共3页
Medical Journal of West China
关键词
帕利哌酮缓释片
首发精神分裂症
血脂代谢
Paliperidone extended-release tablets
Starting schizophrenia~ Blood lipid metabolism
